An appropriate glycemic control seems to decrease the risk of HCC; however, the effect of each diabetes therapy is contradictory, since some studies have found a benefit for metformin but not for insulin or sulfonylureas [64,80,81,82]. Here, INS is linked to hepatocellular carcinoma.